ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER . (2022). World Bulletin of Public Health, 12, 66-69. https://scholarexpress.net/index.php/wbph/article/view/1135